In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 102, Issue 2, 1998, Pages 528-531

  Morabito, Fortunato ^a   Stelitano, Caterina ^a   Callea, Ida ^a   Dattola, Antonella ^a   Console, Giuseppe ^a   Pucci, Giulia ^a   Iacopino, Pasquale ^a   Callea, Vincenzo ^a   Di Raimondo, Francesco ^b   Brugiatelli, Maura ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

CLL; Cytotoxicity; Fludarabine; MTT assay; Response

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LETHAL DOSE 50; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; VIDARABINE;

EID: 7344257742     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00813.x     Document Type: Article

References (11)

1. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
2. Danhauser, L., Plunkett, W., Keating, M. & Cabanillas, F. (1986) 9-Beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells with relapsed leukemia and lymphoma. Cancer Chemotherapy and Pharmacology, 18, 142-145.
3. Dighiero, G. (1997) Chronic lymphocytic leukemia treatment. Hematology and Cell Therapy, 39, S31-S40.
4. + leukaemic B cells: in vitro/in vivo correlations. British Journal of Haematology, 99, 147-157.
5. Hilgenfeld, E., Knauf, W.U. & Thiel, E. (1995) Cytotoxicity of fludarabine in vitro cannot predict clinical outcome in patients with advanced stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia, 9, 541-546.
6. Jaksic, B. & Vitale, B. (1981) Total tumour mass score (TTM): a new parameter in chronic lymphocytic leukaemia. Brithish Journal of Haematology, 49, 401-413.
7. Johnson, S., Smith, A.G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P.J., Hiddemann, W., and the French Cooperative Group on CLL (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet, 347, 1432-1438.
8. Juliusson, G. (1997) Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy, 39, S41-S44.
9. Keating, M.J., O'Brien, S., Kantarjian, H., Plunket, W., Estey, E., Koller, C., Beran, M. & Freireich, E.J. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 81, 2878-2884.
10. Morabito, F., Stelitano, C., Callea, I., Filangeri, M., Oliva, B., Sculli, G., Callea, V., Nobile, F. & Brugiatelli, M. (1996) In vitro chemosensitivity of chronic lymphocytic leukemia B-cells to fludarabine. 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica, 8, 224-231.
11. Silber, R., Degar, B., Costin, D., Newcomb, E. W., Mani, M., Rosemberg, C.R., Morse, L., Drygas, J.C., Canellakis, Z.N. & Potmesil, M. (1994) Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood, 84, 3440-3446.